Effectiveness of mobile health solutions in lowering glycated hemoglobin and resulting economic effects-a review of the current literature

Jonathan C. Javitt

Research output: Contribution to journalArticle

Abstract

Background: In recent years, a variety of innovative solutions have been introduced that are designed to improve adherence to blood sugar testing among patients with diabetes, lower glycated hemoglobin (HbA1c), and decrease complications associated with diabetes mellitus. The value of lowering HbA1c in preventing long-term complications of diabetes is broadly recognized. The purpose of this review is to provide an overview of the peer-reviewed literature documenting both the efficacy of mobile health (mHealth) solutions in improving adherence and lowering HbA1c, along with the impact of lowering HbA1c on near-term cost and complications of diabetes. Methodology: An extensive search of Index Medicus was performed in order to identify studies documenting the effectiveness of mHealth solutions in reducing HbA1c and documenting the effectiveness of reducing HbA1c in lowering near-term medical costs. Results: Six randomized controlled trials were identified in which the use of mobile monitoring solutions for blood glucose was tested against standard care. All demonstrated a reduction in HbA1c, ranging from 0.35-1.9 percentage points. Ten studies, primarily longitudinal and retrospective in nature, were identified, which evaluated the effectiveness of HbA1c reduction on reducing near-term medical costs. Overall, moderate reduction in HbA1c appears to reduce medical costs by 10 % on average in commercially insured populations and 7 % on average in Medicare-age populations. Conclusions: mHealth interventions for diabetes show promise in reducing HbA1c across multiple settings and achieving this clinical result is likely to result in reduction of near-term medical costs.

Original languageEnglish (US)
Pages (from-to)98-102
Number of pages5
JournalUS Endocrinology
Volume10
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Telemedicine
Glycosylated Hemoglobin A
Economics
Costs and Cost Analysis
Diabetes Complications
Blood Glucose
Medicare
MEDLINE
Population
Longitudinal Studies
Diabetes Mellitus
Randomized Controlled Trials
Retrospective Studies

Keywords

  • Cellular communication
  • Cost-effectiveness
  • Diabetes
  • Economic analysis
  • EHealth
  • Glucose monitoring
  • MHealth
  • Mobile health
  • Remote monitoring
  • Wireless communication

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Effectiveness of mobile health solutions in lowering glycated hemoglobin and resulting economic effects-a review of the current literature. / Javitt, Jonathan C.

In: US Endocrinology, Vol. 10, No. 2, 2014, p. 98-102.

Research output: Contribution to journalArticle

@article{34c5687ce88e4388898c46aeb468fb52,
title = "Effectiveness of mobile health solutions in lowering glycated hemoglobin and resulting economic effects-a review of the current literature",
abstract = "Background: In recent years, a variety of innovative solutions have been introduced that are designed to improve adherence to blood sugar testing among patients with diabetes, lower glycated hemoglobin (HbA1c), and decrease complications associated with diabetes mellitus. The value of lowering HbA1c in preventing long-term complications of diabetes is broadly recognized. The purpose of this review is to provide an overview of the peer-reviewed literature documenting both the efficacy of mobile health (mHealth) solutions in improving adherence and lowering HbA1c, along with the impact of lowering HbA1c on near-term cost and complications of diabetes. Methodology: An extensive search of Index Medicus was performed in order to identify studies documenting the effectiveness of mHealth solutions in reducing HbA1c and documenting the effectiveness of reducing HbA1c in lowering near-term medical costs. Results: Six randomized controlled trials were identified in which the use of mobile monitoring solutions for blood glucose was tested against standard care. All demonstrated a reduction in HbA1c, ranging from 0.35-1.9 percentage points. Ten studies, primarily longitudinal and retrospective in nature, were identified, which evaluated the effectiveness of HbA1c reduction on reducing near-term medical costs. Overall, moderate reduction in HbA1c appears to reduce medical costs by 10 {\%} on average in commercially insured populations and 7 {\%} on average in Medicare-age populations. Conclusions: mHealth interventions for diabetes show promise in reducing HbA1c across multiple settings and achieving this clinical result is likely to result in reduction of near-term medical costs.",
keywords = "Cellular communication, Cost-effectiveness, Diabetes, Economic analysis, EHealth, Glucose monitoring, MHealth, Mobile health, Remote monitoring, Wireless communication",
author = "Javitt, {Jonathan C.}",
year = "2014",
doi = "10.17925/USE.2014.10.02.98",
language = "English (US)",
volume = "10",
pages = "98--102",
journal = "US Endocrinology",
issn = "1758-3918",
publisher = "Touch Briefings",
number = "2",

}

TY - JOUR

T1 - Effectiveness of mobile health solutions in lowering glycated hemoglobin and resulting economic effects-a review of the current literature

AU - Javitt, Jonathan C.

PY - 2014

Y1 - 2014

N2 - Background: In recent years, a variety of innovative solutions have been introduced that are designed to improve adherence to blood sugar testing among patients with diabetes, lower glycated hemoglobin (HbA1c), and decrease complications associated with diabetes mellitus. The value of lowering HbA1c in preventing long-term complications of diabetes is broadly recognized. The purpose of this review is to provide an overview of the peer-reviewed literature documenting both the efficacy of mobile health (mHealth) solutions in improving adherence and lowering HbA1c, along with the impact of lowering HbA1c on near-term cost and complications of diabetes. Methodology: An extensive search of Index Medicus was performed in order to identify studies documenting the effectiveness of mHealth solutions in reducing HbA1c and documenting the effectiveness of reducing HbA1c in lowering near-term medical costs. Results: Six randomized controlled trials were identified in which the use of mobile monitoring solutions for blood glucose was tested against standard care. All demonstrated a reduction in HbA1c, ranging from 0.35-1.9 percentage points. Ten studies, primarily longitudinal and retrospective in nature, were identified, which evaluated the effectiveness of HbA1c reduction on reducing near-term medical costs. Overall, moderate reduction in HbA1c appears to reduce medical costs by 10 % on average in commercially insured populations and 7 % on average in Medicare-age populations. Conclusions: mHealth interventions for diabetes show promise in reducing HbA1c across multiple settings and achieving this clinical result is likely to result in reduction of near-term medical costs.

AB - Background: In recent years, a variety of innovative solutions have been introduced that are designed to improve adherence to blood sugar testing among patients with diabetes, lower glycated hemoglobin (HbA1c), and decrease complications associated with diabetes mellitus. The value of lowering HbA1c in preventing long-term complications of diabetes is broadly recognized. The purpose of this review is to provide an overview of the peer-reviewed literature documenting both the efficacy of mobile health (mHealth) solutions in improving adherence and lowering HbA1c, along with the impact of lowering HbA1c on near-term cost and complications of diabetes. Methodology: An extensive search of Index Medicus was performed in order to identify studies documenting the effectiveness of mHealth solutions in reducing HbA1c and documenting the effectiveness of reducing HbA1c in lowering near-term medical costs. Results: Six randomized controlled trials were identified in which the use of mobile monitoring solutions for blood glucose was tested against standard care. All demonstrated a reduction in HbA1c, ranging from 0.35-1.9 percentage points. Ten studies, primarily longitudinal and retrospective in nature, were identified, which evaluated the effectiveness of HbA1c reduction on reducing near-term medical costs. Overall, moderate reduction in HbA1c appears to reduce medical costs by 10 % on average in commercially insured populations and 7 % on average in Medicare-age populations. Conclusions: mHealth interventions for diabetes show promise in reducing HbA1c across multiple settings and achieving this clinical result is likely to result in reduction of near-term medical costs.

KW - Cellular communication

KW - Cost-effectiveness

KW - Diabetes

KW - Economic analysis

KW - EHealth

KW - Glucose monitoring

KW - MHealth

KW - Mobile health

KW - Remote monitoring

KW - Wireless communication

UR - http://www.scopus.com/inward/record.url?scp=84987933725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987933725&partnerID=8YFLogxK

U2 - 10.17925/USE.2014.10.02.98

DO - 10.17925/USE.2014.10.02.98

M3 - Article

VL - 10

SP - 98

EP - 102

JO - US Endocrinology

JF - US Endocrinology

SN - 1758-3918

IS - 2

ER -